Spots Global Cancer Trial Database for Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
Official Title: A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
Study ID: NCT01995058
Study Description
Brief Summary: This study is designed to evaluate the safety and efficacy of combining abiraterone (with prednisone) with cabozantinib in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
, Scottsdale, Arizona, United States
, Sedona, Arizona, United States
, Tucson, Arizona, United States
, Oxnard, California, United States
, San Diego, California, United States
, Aurora, Colorado, United States
, Aurora, Colorado, United States
, Athens, Georgia, United States
, Atlanta, Georgia, United States
, Peoria, Illinois, United States
, Wichita, Kansas, United States
, Las Vegas, Nevada, United States
, Raleigh, North Carolina, United States
, Tualatin, Oregon, United States
, Charleston, South Carolina, United States
, Greenville, South Carolina, United States
, Myrtle Beach, South Carolina, United States
, Dallas, Texas, United States
, Houston, Texas, United States
, Salt Lake City, Utah, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
